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Figure 1. Effect of MTA on STAT1 Tyrosine Phosphorylation
MTA was dissolved either in DMSO or directly in tissue culture
medium. MTA was added to the cells 1 hr prior to stimulation with
IFN (1,000 u/ml) for 30 min. Cell lysates were probed with p(Y701)S-Response to Matters Arising
TAT1 or STAT1 antisera.
to our findings. The authors further state that “… the
same observations were also made for STAT6 (Chen et
al., 2004).” Meissner et al. incubated the cells with MTAIn their Matters Arising article, Meissner et al. present
several experiments that call into question our conclu- in DMSO, whereas we had solubilized MTA in tissue
culture media. While somewhat unexpected, this differ-sions from the results reported in our original manuscript
(Mowen et al., 2001). We clearly acknowledge the impor- ence in solvents used seems to make a significant differ-
ence (see Figure 1): when dissolved in DMSO, MTA doestance of these new findings, but at the same time have
reservations about the extent to which these results indeed block STAT1 tyrosine phosphorylation. However,
when MTA is dissolved in media (as was done in ourinvalidate our conclusions of STAT1 arginine methyl-
ation. original studies to completely block IFN/-mediated
ISG induction), no inhibition of STAT1 tyrosine phos-We had employed monoclonal antibodies against di-
methylarginine (DMA) to demonstrate methylation of phorylation is observed. While we cannot offer an expla-
nation for these different, solvent-dependent effects ofSTAT1 in vivo. Since the antibody was ineffective in
Western blots, we performed immunoprecipiations, fol- MTA, the finding nevertheless invalidates the notion that
mere inhibition of STAT1 tyrosine phosphorylation ac-lowed by anti-STAT1 immunoblotting. Specificity of the
antibodies was demonstrated by the fact that only a counts for the inhibitory effects of MTA on IFN/-induced
gene transcription. In addition, the paper reportingmethylated STAT1 N-terminal domain could success-
fully compete for binding to the DMA antibody. Other STAT6 arginine methylation quoted in this context by
the authors clearly shows that STAT6, but not STAT1labs have in the meantime reproduced these findings
for STAT1, STAT3, and STAT6 (Chen et al., 2004; Duong tyrosine phosphorylation is inhibited by the methyltrans-
ferase inhibitors (Chen et al., 2004: Figure 6B). Lastly,et al., 2004; Rho et al., 2001). However, despite the use
of high-stringent immunoprecipitation condition, coim- MTA-mediated inhibition of STAT1 tyrosine phosphory-
lation cannot explain the increased PIAS associationmunoprecipitation of STAT proteins with associated, ar-
ginine-methylated proteins can naturally not be defini- with hypomethylated STAT1 we and others have ob-
served (Duong et al., 2004). The fact that MTA alsotively excluded in these experiments. However, Rho et
al. reported the arginine methylation of STAT3 (Rho et blocks an NF-B luciferase does not justify the conclu-
sion that it is a nonspecific transcriptional inhibitor. Theal., 2001). This study not only used the DMA antibody
for immunoprecipitation followed by STAT3 Western inhibitory effect of MTA on LPS-mediated NF-B activa-
tion has been previously reported; however, the sameblotting but also successfully employed the DMA anti-
body for Western blotting of STAT3 immunoprecipitates paper provides clear evidence for significantly increased
IL-10 production under these conditions (Hevia et al.,to demonstrate STAT3 arginine methylation (Rho et al.,
2001, Figure 2). 2004). We have also shown in our manuscript that c-fos
induction by serum is not affected by MTA. Lastly, in aIn the metabolic labeling experiments using L-[methyl-
3H]methionine, the incorporation of radioisotope is not follow-up paper published in 2002 we had used different
methylation inhibitors, which like MTA caused abroga-restricted to arginine residues, as lysines as well as
COOH termini can also be methylated. It would therefore tion of IFN/-induced transcription without blocking
STAT1 tyrosine phosphorylation (Zhu et al., 2002).be helpful to know whether the authors were able to
detect radioisotope incorporation into other proteins Our own mass spectrometry data, which had iden-
tified peptides of the appropriate molecular massknown to be arginine methylated on a single residue
(e.g., Sam68, CBP, EWS). (Supplemental Figure S1 at http://www.cell.com/cgi/
content/full/119/5/589/DC1/), and the concurring resultsDr. Vinkemeier’s group further reports that in their
hands the methylation inhibitor MTA blocks tyrosine we had obtained from the mutational analysis of STAT1
R31 may have mislead us into the conclusion that R31phosphorylation of STAT1, which is in striking contrast
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is the site of methylation. The alternative interpretation
of the results we had obtained with the STAT1 R31
mutants as offered by Dr. Vinekmeier’s group is certainly
compelling (although it does not disprove STAT1 meth-
ylation). It is nevertheless surprising that STAT1 R31
mutants or NH2-terminal deletions act as gain-of-func-
tion mutants in the presence of endogenous wild-type
STAT1 (Mowen et al., 2001; Shuai et al., 1996).
In summary, we concur that the new evidence pre-
sented by Meissner et al. clearly merits further investiga-
tions and a re-evaluation of our initial conclusions from
our results. The alternative interpretations of the data
obtained from our original studies (e.g., R31 mutants,
MS) offered here do call into question whether STAT1
is methylated on R31. However, it is important to note
that arginine methylation of STAT1 at a different residue
cannot be excluded on the basis of the presented exper-
iments.
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